In our opinion, in addition to assessing patients for PD-L1 expression in the tumor, the expression of PD-1 in the tumor could serve as a potential biomarker to define efficacy or tumor progression following immunotherapy with either anti-PD-1 o anti-PD-L1 monoclonal antibodies (13). This evidence concerns the gene CD274 and neoplasm.